Orion Porfolio Solutions LLC Sells 7,727 Shares of Thermo Fisher Scientific Inc. $TMO

Orion Porfolio Solutions LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.8% in the third quarter, HoldingsChannel reports. The firm owned 19,102 shares of the medical research company’s stock after selling 7,727 shares during the period. Orion Porfolio Solutions LLC’s holdings in Thermo Fisher Scientific were worth $9,265,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Stonebridge Capital Advisors LLC grew its stake in Thermo Fisher Scientific by 0.5% during the third quarter. Stonebridge Capital Advisors LLC now owns 25,659 shares of the medical research company’s stock worth $12,445,000 after buying an additional 130 shares during the last quarter. Snyder Capital Management L P grew its position in Thermo Fisher Scientific by 71.6% during the 3rd quarter. Snyder Capital Management L P now owns 98,285 shares of the medical research company’s stock worth $47,670,000 after acquiring an additional 40,997 shares during the last quarter. Corient IA LLC raised its position in Thermo Fisher Scientific by 100.0% in the 3rd quarter. Corient IA LLC now owns 1,000 shares of the medical research company’s stock valued at $485,000 after purchasing an additional 500 shares during the last quarter. Alpha Family Trust bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth $342,000. Finally, Element Pointe Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 3.2% in the third quarter. Element Pointe Advisors LLC now owns 1,595 shares of the medical research company’s stock valued at $774,000 after buying an additional 50 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 3.3%

NYSE:TMO opened at $501.72 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The business’s 50-day simple moving average is $567.28 and its 200-day simple moving average is $548.32. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The stock has a market capitalization of $186.38 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.99 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same period in the prior year, the business earned $6.10 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.70%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TMO shares. Robert W. Baird set a $653.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. The Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target for the company. Stifel Nicolaus upped their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Finally, HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.